Nathan L. Mata
Technik-/Wissenschafts-/F&E-Leiter bei BELITE BIO, INC
Aktive Positionen von Nathan L. Mata
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BELITE BIO, INC | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2021 | - |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2021 | - |
Karriereverlauf von Nathan L. Mata
Ehemalige bekannte Positionen von Nathan L. Mata
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Trethera Corp.
Trethera Corp. Miscellaneous Commercial ServicesCommercial Services Trethera Corp. operates as a biopharmaceutical firm. The company was founded by Caius Radu, Johannes Czernin, David Nathanson, Owen N. Witte and Michael E. Jung and is headquartered in Sherman Oaks, CA. | Geschäftsführer | 01.01.2015 | 01.01.2017 |
Technik-/Wissenschafts-/F&E-Leiter | 01.01.2015 | 01.01.2017 | |
ReVision Therapeutics, Inc.
ReVision Therapeutics, Inc. Drugstore ChainsRetail Trade ReVision Therapeutics, Inc. develops drugs for the treatment of age-related macular degeneration diseases. The firm operates as a ophthalmic biopharmaceutical company. Its products include Fenretinide, an oral medication that reduces the accumulation of A2E in the retina, and slows down the growth of atrophic lesions, which precedes vision loss. The company was founded in April 2010 and is headquartered in La Jolla, CA. | Technik-/Wissenschafts-/F&E-Leiter | 03.11.2010 | 01.01.2012 |
Gründer | 01.04.2010 | 01.01.2012 | |
Sirion Therapeutics, Inc.
Sirion Therapeutics, Inc. BiotechnologyHealth Technology Sirion Therapeutics, Inc. provides biopharmaceutical products and services. It manufactures, develops and commercialize ophthalmic products for eye diseases. The company was founded by Barry Butler, Susan Benton, Philippe Boulangeat and Roger Vogel in November 2005 and is headquartered in Tampa, FL. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2006 | 01.01.2010 |
Sytera, Inc.
Sytera, Inc. BiotechnologyHealth Technology Part of Bausch Health Cos., Inc., Sytera, Inc. is a biopharmaceutical company that provides biopharmaceutical services and products. The company is based in La Jolla, CA. The company was founded by Jay B. Lichter, Kenneth J. Widder, Nathan L. Mata. Sytera was acquired by Sirion Therapeutics, Inc. on August 16, 2006 for $250 million. | Direktor/Vorstandsmitglied | 01.01.2004 | 01.01.2006 |
Gründer | 01.01.2004 | 01.01.2006 | |
Jules Stein Eye Institute
Jules Stein Eye Institute Other Consumer ServicesConsumer Services Part of University of California, Jules Stein Eye Institute operates as an eye institute. The company is based in Los Angeles, CA. | Corporate Officer/Principal | - | - |
Ausbildung von Nathan L. Mata
The University of Texas at Austin | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 9 |
Operativ
Chief Tech/Sci/R&D Officer | 5 |
Founder | 2 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Retail Trade | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BELITE BIO, INC | Health Technology |
Private Unternehmen | 6 |
---|---|
ReVision Therapeutics, Inc.
ReVision Therapeutics, Inc. Drugstore ChainsRetail Trade ReVision Therapeutics, Inc. develops drugs for the treatment of age-related macular degeneration diseases. The firm operates as a ophthalmic biopharmaceutical company. Its products include Fenretinide, an oral medication that reduces the accumulation of A2E in the retina, and slows down the growth of atrophic lesions, which precedes vision loss. The company was founded in April 2010 and is headquartered in La Jolla, CA. | Retail Trade |
Sirion Therapeutics, Inc.
Sirion Therapeutics, Inc. BiotechnologyHealth Technology Sirion Therapeutics, Inc. provides biopharmaceutical products and services. It manufactures, develops and commercialize ophthalmic products for eye diseases. The company was founded by Barry Butler, Susan Benton, Philippe Boulangeat and Roger Vogel in November 2005 and is headquartered in Tampa, FL. | Health Technology |
Sytera, Inc.
Sytera, Inc. BiotechnologyHealth Technology Part of Bausch Health Cos., Inc., Sytera, Inc. is a biopharmaceutical company that provides biopharmaceutical services and products. The company is based in La Jolla, CA. The company was founded by Jay B. Lichter, Kenneth J. Widder, Nathan L. Mata. Sytera was acquired by Sirion Therapeutics, Inc. on August 16, 2006 for $250 million. | Health Technology |
Jules Stein Eye Institute
Jules Stein Eye Institute Other Consumer ServicesConsumer Services Part of University of California, Jules Stein Eye Institute operates as an eye institute. The company is based in Los Angeles, CA. | Consumer Services |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | Health Technology |
Trethera Corp.
Trethera Corp. Miscellaneous Commercial ServicesCommercial Services Trethera Corp. operates as a biopharmaceutical firm. The company was founded by Caius Radu, Johannes Czernin, David Nathanson, Owen N. Witte and Michael E. Jung and is headquartered in Sherman Oaks, CA. | Commercial Services |
- Börse
- Insiders
- Nathan L. Mata
- Erfahrung